To conduct applied epidemiological and economic research to inform public health decisions about vaccination.
Epidemiological and economic research to support evidence-based public health decision making about vaccination.
To conduct applied epidemiological and economic research to inform public health decisions about vaccination.
Conducting UK-based research in collaboration with Public Health England to inform recommendations by the Joint Committee on Vaccines and Immunisation (JCVI) and other key stakeholders.
Conducting research to inform funding decisions and global recommendations by international organisations including WHO, Gavi, the Vaccine Alliance and BMGF.
Conducting research to support vaccine decision-making in countries across the world, including high-, middle- and low-income countries. Our country-based work is always done in collaboration with local researchers and stakeholders.
- Strengthening capacity in China for vaccine research and decision making
To collaborate with key public health and academic partners in China in order to generate evidence and support evidence-based policy-making around the introduction of new vaccines.
- NIHR Health Protection Research Unit on Immunisation
The National Institute for Health Research (NIHR) Health Protection Research Unit in Immunisation is a unique partnership between the London School of Hygiene & Tropical Medicine and Public Health England creating a dynamic fusion of academic research and public health implementation that rapidly translates scientific advances in immunization into measurable benefits for society.
- Vaccine Impact Modelling Consortium
The Vaccine Impact Modelling Consortium coordinates the work of several research groups modelling the impact of vaccination programmes worldwide. As part of the consortium, we are focused on estimating the health impact of Hib, HPV, measles, pneumococcal and rotavirus vaccines.
- Health and Economic Impact of Hib, Pneumococcal, Rotavirus and HPV vaccination in Sudan
To estimate the health and economic impact of Hib, Pneumococcal, Rotavirus and HPV (not yet introduced) vaccination in Sudan. This evidence on the value of vaccines will be beneficial to Sudan's Ministry of Health and their partners in developing a domestic resource mobilisation strategy for the national immunisation programme, particularly following the anticipated accelerated Gavi transition starting in 2021.
- Group B Streptococcus Vaccination
Evaluation of the impact and cost-effectiveness of maternal Group B Strep vaccines and immunization strategies worldwide.
- Single-Dose HPV Vaccine Evaluation Consortium
The Single-Dose HPV Vaccine Evaluation Consortium, coordinated by PATH and encompassing nine leading research institutions, has begun work to collate and synthesise existing evidence and evaluate new data on the potential for single-dose human papillomavirus (HPV) vaccine delivery.
- COVID-19 Vaccination Strategies
To model the health impact of alternative dosing schedules and maximise the health impact of limited COVID-19 vaccine supplies in low- and middle-income countries.
- Measles-Rubella Multi-Array Patches full value assessment
Full value assessment of measles-rubella multi-array patches through scenario analysis of their impact on measles burden and economic benefits.
The group is supported by a range of UK-based (MRC, NIHR, Wellcome Trust) and international (BMGF, European Union, Gavi, UNICEF, WHO) funders.
- Albert Jan van Hoek
- Alicia Rosello
- Andrew Clark
- Billy Quilty
- Carl Pearson
- Charlie Diamond
- Christinah Mukandavire
- Fabienne Krauer
- George Qian
- Han Fu
- Hira Tanvir
- Ifedayo Adetifa
- James Munday
- Jiayao Lei
- John Edmunds
- Kaja Abbas
- Katherine Atkins
- Kathleen O'Reilly
- Kevin van Zandvoort
- Kiesha Prem
- Mark Jit
- Megan Auzenbergs
- Mihaly Koltai
- Nicholas Davies
- Petra Klepac
- Rosalind Eggo
- Sam Clifford
- Sebastian Funk
- Simon Procter
- Stefan Flasche
- Yang Liu
- Anna Carnegie
- Jake Watts
- Akira Endo
- Alexis Robert
- Alyssa Sbarra
- Caroline Mburu
- David Hodgson
- Deus Thindwa
- Jada Hackman
- Moritz Wagner
- Naomi Waterlow
- Noriko Kitamura
- Palwasha Anwari
- Yung-Wai Chan
Scientists, Public Health England
- Emilia Vynnycky
- Frank Sandmann
- Marc Baguelin
We are interested in new collaborations with researchers and decision-makers on epidemiological and economic analyses to inform public health decisions about vaccination in any setting.
We work closely with a multidisciplinary group of vaccine researchers, including biostatisticians, clinicians, computer scientists, epidemiologists and social scientists. We are closely linked with both the Centre for the Mathematical Modelling of Infectious Diseases and the Vaccine Centre at LSHTM.
Our collaborations include:
- Modelling and Economics Unit, Centre of Infectious Disease Surveillance and Control, and Viral Reference Laboratory, Public Health England
- Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), University of Antwerp
- Brisson Lab, University of Laval
- School of Public Health, University of Hong Kong
- Saw Swee Hock School of Public Health (SSHSPH), National University of Singapore
- Newall Lab, University of New South Wales
- Yu Lab, Fudan University
- Health Intervenion and Technology Assessment Program, Thailand
- University of Cambridge
- Biocomplexity Institute, University of Virginia
- International Vaccine Institute
- Evidence to policy pathway to immunisation in China
We conduct applied vaccine research to help decision makers in China build a vaccination programme that ensures reliable, affordable, equitable and uninterrupted supply of vaccines to the Chinese population.
Start and end date
1 Aug 2017 to 31 Jul 2020
In China, many newer vaccines are not centrally funded, so people pay for them out-of-pocket. China is investigating whether to increase the range of vaccines that are fully funded by central government. This will require a lot of money and manufacturing capacity to supply China’s large population. Hence, authorities in China need evidence of the potential health benefits, budget impact and value for money of investments in funding new vaccines. In addition, sufficient and reliable public demand needs to be assured so that local manufacturers will ensure a reliable and uninterrupted vaccine supply. Maintaining public confidence in vaccines in the face of concerns around vaccine safety is also important.
The NIHR-funded Evidence to Policy pathway to Immunisation in China (EPIC) Global Health Research Group brings four British and Chinese public health and academic partners: the London School of Hygiene & Tropical Medicine (LSHTM), Public Health England (PHE), Chinese Centre for Disease Control and Prevention (China CDC) and Fudan University (Fudan). EPIC’s structure is inspired by the NIHR-funded Health Protection Research Unit in Immunisation, in which LSHTM and PHE jointly conduct research to inform UK vaccine policy.
Together, we conduct applied vaccine research that will help decision-makers in China build a vaccination programme that ensures reliable, affordable, equitable and uninterrupted supply of vaccines to the Chinese population.
Our work spans three themes:
- Collecting and analysing data about health and economic consequences of vaccine-preventable diseases in China
- Understanding vaccine supply, demand and decision making among the public, manufacturers and key stakeholders
- Using findings from themes (1) and (2) in mathematical models to project the health and economic impact that vaccine introduction could have, particularly among the groups with the worst health. We will focus research around vaccines that are of most interest to decision-makers but are not currently centrally funded
We aim for EPIC to inspire similar models of research to inform immunisation policy elsewhere in Asia. We will publicise key insights from this collaborative work widely, and hold workshops in Asia towards the end of the grant to share lessons learnt with other Asian countries. Through these channels, we will invite partners outside China to explore funding opportunities to establish similar models in other countries.
Partners and collaborators
- Chinese Center for Disease Control & Prevention, China
- Fudan University, China
- Public Health England
EPIC will be a collaboration between the UK and China involving reciprocal exchanges of staff. Scientists in China draw on British expertise as they design studies to collect and analyse data. Chinese PhD students and visiting scientists come to LSHTM and PHE and are supervised by UK experts to conduct analyses and build models. British scientists work with teams in China to gain a deep understanding of vaccine epidemiology, data collection and policy making in China. Findings will be presented to key groups in China responsible for making decisions about vaccine delivery.
- UK-China Joint National Immunisation Leaders Exchange 2019
On 3-7 June 2019, NIHR EPIC organized a visit by leaders involved in decision-making and implementation of the national immunisation programme in China. The delegation was led by Dr Zijian Feng, Deputy Director-General of the Chinese Center for Disease Control and Prevention (China CDC). The Chinese delegation spent 5 days in London, and had the opportunity to interact with key policy-makers, public health officials and researchers from Public Health England (PHE), LSHTM, NHS England, NIHR and the Greater London Authority.
The purpose of the visit was to:
- Exchange knowledge about the current public health practice of the national immunization program and vaccination services in UK and China;
- Discuss and demonstrate how policy-relevant immunization research provides evidence to inform vaccine policy
- Strengthen the relationship between Public Health England and China CDC in immunization
Highlights of the five days included:
- A visit to PHE Wellington House to meet officers from PHE, the Greater London Authority and NHS England to exchange knowledge about the current immunization and vaccination services in UK and China
- An off-site visit to a local vaccination clinic to deepen the understanding of how vaccination services are carried out and well monitored in UK
- A visit to PHE Colindale to attend a workshop of role of JCVI in the UK and NIAC in China, including demonstration of the work undertaken in the Immunization Service at PHE and challenges of new vaccine introduction in China
- Observing the Joint Committee on Vaccination and Immunization meeting
- Participating in the annual scientific advisory board meeting to guide the strategic direction of NIHR EPIC
- A visit to LSHTM to attend the Vaccine Centre UK-China symposium: evidence to inform vaccine policy, which provided an opportunity for scientific exchange between Chinese delegates and researchers at LSHTM. The event showcased policy- relevant immunization research carried out at LSHTM, PHE, China CDC and Fudan University, with focus on immunization in China and the UK
- NIHR EPIC training workshop on mathematical modelling of infectious diseases
On 12-14 August 2019, NIHR EPIC members from LSHTM, Fudan University and the University of Hong Kong organized a training workshop on infectious disease modelling to build capacity in this area in China. The workshop was held at Fudan University in Shanghai and attracted 65 attendees from universities and public health institutions across China.
The course covered a wide range of topics including modelling transmission of infectious diseases, health economic analysis, geospatial modelling and phylodynamic analyses.
- NIHR EPIC involvement in HTAsiaLink 2019
Mark Jit, the Director of NIHR EPIC, participated in the 8th HTAsiaLink Annual Conference in Seoul, South Korea on 24-27 April 2019 in order to generate awareness and interest in the work of NIHR EPIC. This was the opportunity to organise a workshop on “Conducting economic evaluations of vaccination: lessons from the field and opportunities for further collaboration”. The aim of the workshop was to explore interest from participants in being part of a proposal to extend NIHR EPIC to other countries in the region, as requested by NIHR.
The workshop was attended by 39 participants from Australia, Canada, China, India, Kenya, Malaysia, the Philippines, South Korea, Singapore, Switzerland, Taiwan, Thailand, the United Kingdom and Vietnam. Many of the participants were from key health technology agencies in the region such as the National Evidence-based Healthcare Collaborating Agency (NECA) in South Korea, Health Intervention and Technology Assessment Program (HITAP) in Thailand, the Center for Drug Evaluation in Taiwan and the Malaysian Health Technology Assessment Section (MAHTAS) in Malaysia.
Many of the participants expressed interest in being part of future NIHR research funding proposals, and we will contact them when the opportunities arise.